GET DAILY SIGNALSAlvotech (ALVO): Biosimilars Growth and What It Means for Investors
Key Takeaways
- Alvotech (ALVO) is an Iceland-headquartered biotechnology company focused exclusively on developing and manufacturing biosimilar medicines.
- Founded in 2013 by Robert Wessman, the company went public through a business combination with a special purpose acquisition company (SPAC) in June 2022.
- Alvotech has five approved and marketed biosimilars, including versions of Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva.
- The company relies on a network of commercial partners, most notably Teva Pharmaceutical Industries (TEVA), to distribute its products globally.
- Its business model centers on integrated development and manufacturing capabilities, supported by an expanding pipeline of biosimilar candidates.
Company Background
Alvotech (ALVO) develops and manufactures biosimilar medicines, which are lower-cost alternatives to established biologic drugs. These products aim to improve patient access while helping control healthcare costs. The company’s focus on this niche gives investors exposure to a growing segment of the pharmaceutical industry, with partnerships extending across the United States, Europe, Japan, China, and other key markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Profile and Operations
Founded in 2013 by Robert Wessman, who previously built Alvogen and led Actavis Group, Alvotech is based in Reykjavik, Iceland. Its main site handles research, development, and manufacturing. The company went public via a SPAC merger with Oaktree Acquisition Corp II on June 15, 2022, and began trading on Nasdaq the next day. It also trades on Nasdaq Iceland and has depository receipts listed in Sweden.
Alvotech’s approach integrates development, regulatory work, and manufacturing in-house, while relying on partners for commercialization. Revenue comes from product sales, service fees, and licensing through these collaborations. Five biosimilars are already approved and marketed, covering references to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab). These target autoimmune, eye, and bone conditions. The pipeline includes further candidates in autoimmune disease, osteoporosis, respiratory issues, and oncology.
A key relationship is the exclusive U.S. commercialization deal with Teva Pharmaceutical Industries (TEVA) for the Humira biosimilar. Additional regional partners support reach into Europe, Asia, Latin America, Africa, and the Middle East.
Why Investors Track ALVO
From what I see, the main draw is the long-term expansion of the biosimilars market as major biologics lose patent protection. Alvotech’s integrated model and focus on high-revenue reference products position it to capture share in this space. Its high-concentration, citrate-free Humira biosimilar received interchangeable status from the FDA in February 2024, which can facilitate pharmacy-level substitution and wider use. Partnerships provide commercial infrastructure without the need for a full global sales team.
Risks Worth Considering
Competition in biosimilars is intense, which can affect pricing and market share. Alvotech has reported operating losses tied to heavy R&D and manufacturing investments. Regulatory timelines remain uncertain, and patent disputes with originators can delay launches. Heavy reliance on partners like Teva introduces execution risk, while multi-jurisdiction operations expose the company to currency swings and varying regulatory environments.
Using AI Tools in Research
In my own work, Tickeron’s AI Screener serves as a practical way to scan for stocks and ETFs using technical indicators, fundamentals, volatility measures, trends, AI signals, and industry filters. It helps surface ideas that align with specific strategies without manually reviewing thousands of securities. This kind of platform can complement fundamental research on names like Alvotech by highlighting comparable opportunities across sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ALVO's RSI Oscillator climbs out of oversold territory
The RSI Indicator for ALVO moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 27 of the 34 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 63 cases where ALVO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for ALVO just turned positive on November 10, 2026. Looking at past instances where ALVO's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 77 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ALVO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement